Molecular pathways: Targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia

Clinical Cancer Research

Volumn 18, Issue 15, 2012, Pages 4013-4018

  Herman, Sarah E M ^a   Johnson, Amy J ^b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 5 FLUORO 3 PHENYL 2 [1 (9H PURIN 6 YLAMINO)PROPYL] 3H QUINAZOLIN 4 ONE; BENDAMUSTINE; FLUDARABINE; OFATUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOINOSITIDE 3 KINASE P110 DELTA; RITUXIMAB; UNCLASSIFIED DRUG; WORTMANNIN;

ANTINEOPLASTIC ACTIVITY; B LYMPHOCYTE; CANCER COMBINATION CHEMOTHERAPY; CELL FUNCTION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CHEMOSENSITIZATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ASSESSMENT; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME LOCALIZATION; HEMATOPOIETIC CELL; HUMAN; HYPERGLYCEMIA; LEUKEMOGENESIS; LYMPHADENOPATHY; LYMPHOCYTE COUNT; LYMPHOCYTOSIS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VALIDATION PROCESS;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; CLINICAL TRIALS AS TOPIC; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PURINES; QUINAZOLINONES; SIGNAL TRANSDUCTION;

EID: 84864436773     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1402     Document Type: Review

References (40)

1. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7:606-19. (Pubitemid 44100518)
2. Hawkins PT, Anderson KE, Davidson K, Stephens LR. Signalling through class I PI3Ks in mammalian cells. Biochem Soc Trans 2006;34:647-62. (Pubitemid 44796393)
3. Fruman DA. Towards an understanding of isoform specificity in phosphoinositide 3-kinase signalling in lymphocytes. Biochem Soc Trans 2004;32:315-9. (Pubitemid 38582117)
4. Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci 2005;30:194-204. (Pubitemid 40463309)
5. Deane JA, Fruman DA. Phosphoinositide 3-kinase: diverse roles in immune cell activation. Annu Rev Immunol 2004;22:563-98. (Pubitemid 38680434)
6. Niiro H, Clark EA. Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol 2002;2:945-56. (Pubitemid 37323215)
7. Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol 2003;3:317-30. (Pubitemid 37328684)
8. Dal Porto JM, Gauld SB, Merrell KT, Mills D, Pugh-Bernard AE, Cambier J. B cell antigen receptor signaling 101. Mol Immunol 2004;41:599-613. (Pubitemid 38824617)
9. Zhang SQ, Tsiaras WG, Araki T, Wen G, Minichiello L, Klein R, et al. Receptor-specific regulation of phosphatidylinositol 30-kinase activation by the protein tyrosine phosphatase Shp2. Mol Cell Biol 2002;22:4062-72. (Pubitemid 34556577)
10. Koyasu S. The role of PI3K in immune cells. Nat Immunol 2003;4:313-9.
11. Geering B, Cutillas PR, Vanhaesebroeck B. Regulation of class IA PI3Ks: is there a role for monomeric PI3K subunits? Biochem Soc Trans 2007;35:199-203. (Pubitemid 46596467)
12. Chantry D, Vojtek A, Kashishian A, Holtzman DA, Wood C, Gray PW, et al. p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J Biol Chem 1997;272:19236-41. (Pubitemid 27337713)
13. Cantrell DA. Phosphoinositide 3-kinase signalling pathways. J Cell Sci 2001;114:1439-45. (Pubitemid 32427831)
14. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003;4:257-62. (Pubitemid 37329790)
15. Brazil DP, Hemmings BA. Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci 2001;26:657-64. (Pubitemid 33042488)
16. Kim D, Chung J. Akt: versatile mediator of cell survival and beyond. J Biochem Mol Biol 2002;35:106-15. (Pubitemid 35216586)
17. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261-74. (Pubitemid 46962095)
18. Wymann MP, Zvelebil M, Laffargue M. Phosphoinositide 3-kinase signalling-which way to target? Trends Pharmacol Sci 2003;24:366-76. (Pubitemid 37315529)
19. Xu GB, Lu XG, Luo LH, Zhu L. [Detection of soluble Apo-1/Fas in plasma, pleural and ascites fluid of malignant tumor patients and its clinical significance]. Zhejiang Da Xue Xue Bao Yi Xue Ban 2003;32:335-8.
20. Jou ST, Carpino N, Takahashi Y, Piekorz R, Chao JR, Wang D, et al. Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol Cell Biol 2002;22:8580-91. (Pubitemid 35397173)
21. Papakonstanti EA, Zwaenepoel O, Bilancio A, Burns E, Nock GE, Houseman B, et al. Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages. J Cell Sci 2008;121:4124-33.
22. Min SH, Abrams CS. Why do phosphatidylinositol kinases have so many isoforms? Biochem J 2009;423:e5-8.
23. Clayton E, Bardi G, Bell SE, Chantry D, Downes CP, Gray A, et al. A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med 2002;196:753-63.
24. Okkenhaug K, Vanhaesebroeck B. PI3K-signalling in B- and T-cells: insights from gene-targeted mice. Biochem Soc Trans 2003;31:270-4. (Pubitemid 36241443)
25. Kang S, Denley A, Vanhaesebroeck B, Vogt PK. Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci U S A 2006;103:1289-94. (Pubitemid 43191158)
26. Kienle D, Benner A, Krober A, Winkler D, Mertens D, Buhler A, et al. Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes. Blood 2006;107:2090-3. (Pubitemid 43289393)
27. Marshall AJ, Niiro H, Yun TJ, Clark EA. Regulation of B-cell activation and differentiation by the phosphatidylinositol 3-kinase and phospholipase Cgamma pathway. Immunol Rev 2000;176:30-46.
28. Niiro H, Maeda A, Kurosaki T, Clark EA. The B lymphocyte adaptor molecule of 32 kD (Bam32) regulates B cell antigen receptor signaling and cell survival. J Exp Med 2002;195:143-9. (Pubitemid 34074504)
29. Davies CC, Mason J, Wakelam MJ, Young LS, Eliopoulos AG. Inhibition of phosphatidylinositol 3-kinase- and ERK MAPK-regulated protein synthesis reveals the pro-apoptotic properties of CD40 ligation in carcinoma cells. J Biol Chem 2004;279:1010-9. (Pubitemid 38082622)
30. Bilancio A, Okkenhaug K, Camps M, Emery JL, Ruckle T, Rommel C, et al. Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells. Blood 2006;107:642-50. (Pubitemid 43076389)
31. Henley T, Kovesdi D, Turner M. B-cell responses to B-cell activation factor of the TNF family (BAFF) are impaired in the absence of PI3K delta. Eur J Immunol 2008;38:3543-8.
32. Coutre SE, Byrd JC, Furman RR, Brown JR, Benson DM, Wagner-Johnston ND, et al. Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 29:2011 (suppl; abstr 6631).
33. Sharman J, de Vos S, Leonard JP, Furman RR, Coutre SE, Flinn IW, et al. A phase 1 study of the selective phosphatidylinositol 3-kinasedelta (PI3K{delta}) inhibitor, CAL-101 (GS-1101), in combination with rituximab and/or bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 2011;118:1787.
34. Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011;117:591-4.
35. Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010;116:2078-88.
36. Fiorcari S, Brown WS, McIntyre BW, O'Brien S, Sivina M, Hoellenriegel J, et al. The PI3 kinase {delta} inhibitor, CAL-101 (GS-1101), inhibits chronic lymphocytic leukemia (CLL) cell survival in endothelial and marrow stromal cell co-cultures. Blood (ASH Annual Meeting Abstracts) 2011;118:1769.
37. Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, et al. The phosphoinositide 30-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011;118:3603-12.
38. Davids MS, Lannutti BJ, Brown JR, Letai AJ. BH3 profiling demonstrates that restoration of apoptotic priming contributes to increased sensitivity to PI3K inhibition in stroma-exposed chronic lymphocytic leukemia cells. Blood (ASH Annual Meeting Abstracts) 2011;118:974.
39. Furman RR, Byrd JC, Brown JR, Coutre SE, Benson DM, Wagner-Johnston ND, et al. CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts) 2010;116:55.
40. Flinn IW, Schreeder MT, Coutre SE, Leonard J, Wagner-Johnston ND, De Vos S, et al. A phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in combination with anti-CD20 monoclonal antibody therapy and/or bendamustine in patients with previously treated B-cell malignancies. J Clin Oncol 29: 2011 (suppl; abstr 3064).